Literature DB >> 19609951

Frequency of and variables associated with the EGFR mutation and its subtypes.

Tomoaki Tanaka1, Masaru Matsuoka, Akihisa Sutani, Akihiko Gemma, Makoto Maemondo, Akira Inoue, Shoji Okinaga, Makoto Nagashima, Satoshi Oizumi, Kazutsugu Uematsu, Yoshiaki Nagai, Gaku Moriyama, Hitoshi Miyazawa, Kenji Ikebuchi, Satoshi Morita, Kunihiko Kobayashi, Koichi Hagiwara.   

Abstract

Mutation in the epidermal growth factor receptor (EGFR) is frequently seen in non-small cell lung cancers (NSCLCs), especially in Asian females with adenocarcinoma. The frequency of mutation and the factors associated requires to be elucidated by analyzing a large number of consecutive clinical samples. We summarized the result of the EGFR mutation analysis for 1,176 patients performed at the time of diagnosis or relapse. The PNA-LNA PCR clamp, a highly sensitive detection method for the EGFR mutation, was employed. For fresh cases a portion of samples isolated to establish the diagnosis of lung cancer was used. For cases with a relapsed disease archival tissue were tested. The variables associated with the EGFR mutation after removing the confound factors were investigated by the logistic analysis using the samples collected in our university (n = 308) where detailed information on patients were available. The frequency of the EGFR mutation and its subtypes were investigated using all samples (n = 1,176). The EGFR mutation was significantly associated with adenocarcinoma (p = 0.006) and light-smoking (p < 0.0001), but not gender. The deletions in exon 19 were more frequently associated with male gender while exon 21 deletions were with female gender (p = 0.0011). The overall frequency of the EGFR mutation was 31%. Our result suggests that the female predominance in the EGFR mutation rate is a reflection of a higher frequency of adenocarcinoma in females. The gender difference in the mutation subtypes may provide a clue for the mechanism of the occurrence of the EGFR mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19609951     DOI: 10.1002/ijc.24746

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  69 in total

1.  Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.

Authors:  Vei Mah; Diana Marquez; Mohammad Alavi; Erin L Maresh; Li Zhang; Nam Yoon; Steve Horvath; Lora Bagryanova; Michael C Fishbein; David Chia; Richard Pietras; Lee Goodglick
Journal:  Lung Cancer       Date:  2011-04-20       Impact factor: 5.705

Review 2.  Epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Charles N Prabhakar
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Practical innovations for high-throughput amplicon sequencing.

Authors:  Derek S Lundberg; Scott Yourstone; Piotr Mieczkowski; Corbin D Jones; Jeffery L Dangl
Journal:  Nat Methods       Date:  2013-09-01       Impact factor: 28.547

4.  Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

Authors:  Hui Ning; Ming Liu; Lina Wang; Yang Yang; Nan Song; Xiaoxiong Xu; Jin Ju; Gening Jiang
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 5.  Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.

Authors:  Sohita Dhillon
Journal:  Target Oncol       Date:  2015-02-01       Impact factor: 4.493

6.  High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.

Authors:  Mengxi Ge; Yingjie Zhuang; Xinli Zhou; Ruofan Huang; Xiaohua Liang; Qiong Zhan
Journal:  J Neurooncol       Date:  2017-08-05       Impact factor: 4.130

Review 7.  Role of epidermal growth factor receptor in lung cancer and targeted therapies.

Authors:  Tie-Cheng Liu; Xin Jin; Yan Wang; Ke Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

8.  L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report.

Authors:  Xianhong Xiang; Jianxing Yu; Yingrong Lai; Weiling He; Shuhua Li; Liantang Wang; Zunfu Ke
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

9.  Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.

Authors:  Feng Pan; Jing Tian; Xuchao Zhang; Ying Zhang; Yueyin Pan
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

10.  EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.

Authors:  Ramon Andrade de Mello; Filipa Soares Pires; Dânia Sofia Marques; Júlio Oliveira; Ana Rodrigues; Marta Soares; Isabel Azevedo; Ana Peixoto; Catarina Santos; Carla Pinto; Venceslau Hespanhol; Manuel R Teixeira; Teresina Amaro; Henrique Queiroga; António Araújo
Journal:  Tumour Biol       Date:  2012-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.